Antimalarial Efficacy of a Quantified Extract of Nauclea pobeguinii Stem Bark in Human Adult Volunteers with Diagnosed Uncomplicated falciparum Malaria. Part 2: A Clinical Phase IIB Trial

 

 Buy Article Permissions and Reprints

Abstract

According to the promising results of the Phase I and Phase IIA clinical trials with the herbal medicinal product PR 259 CT1 consisting of an 80 % ethanolic extract of the stem bark of Nauclea pobeguinii containing 5.6 % strictosamide, a Phase IIB study was conducted as a single blind prospective trial in 65 patients with proven Plasmodium falciparum malaria to evaluate the effectiveness and safety of this herbal drug. The study was carried out simultaneously using an artesunate-amodiaquine combination (Coarsucam®) as a positive control. This combination is the standard first-line treatment for uncomplicated malaria recommended by the National Programme of Malaria Control in the Democratic Republic of Congo (DR Congo). With regard to PR 259 CT1, patients were treated with a drug regimen of two 500-mg capsules three times daily for three days in the inpatient clinic, followed by out-patient treatment of one 500-mg capsule three times daily during the next four days; the positive control group received two tablets containing 100 mg artesunate and 270 mg amodiaquine (fixed-dose) once daily during three consecutive days. Antimalarial responses were evaluated according to the WHO 2003 guideline for a 14-day test. The results from the physical and laboratory examinations did not show any significant changes in values of vital signs, ECG, biochemical, and haematological parameters. The study showed a significant decreased parasitaemia in patients treated with PR 29 CT1 and artesunate-amodiaquine with adequate clinical parasitological responses (APCR) at day 14 of 87.9 and 96.9 %, respectively. The former product was better tolerated than the latter since more side effects were observed for the artesunate-amodiaquine combination. These results indicated that PR 259 CT1 can be considered as a promising candidate for the development of a herbal medicine for the treatment of uncomplicated falciparum malaria.

• References

• 1 Willcox M, Bodeker G. Traditional herbal medicines for malaria. Br Med J 2004; 329: 1156-1159
  CrossrefPubMedGoogle Scholar
• 2 WHO. Declaration of Alma-Ata. Available at http://www.who.int/hpr/NPH/docs/declaration_almaata.pdf Accessed May 24, 2011
  PubMedGoogle Scholar
• 3 Schuster BG. A new integrated program for natural product development and the value of an ethnomedical approach. J Alternat Complement Med 2001; 7?S: 61-72
  PubMedGoogle Scholar
• 4 WHO. Traditional medicine strategy 2002 – 2005. Geneva: WHO/EDM/TRM; 2002.1 2002
  Google Scholar
• 5 Tangenyi OH. Contribution à lʼétude des plantes médicinales utilisées contre le paludisme au Sankuru. [dissertation]. République Démocratique du Congo: Université Patrice Emery Lumumba, Campus Méthodistes de Wembo-Nyama; 1996
  PubMedGoogle Scholar
• 6 Anam EM. Novel nauclequiniine from the root extract of Nauclea pobeguinii (Pob and Pellegr) Petit (Rubiaceae). Indian J Chem B Org Chem Med Chem 1997; 36: 54-56
  PubMedGoogle Scholar
• 7 Zeches M, Richard B, Gueye-Mʼbahia L, Le Men-Olivier L. Constituants des écorces de racine de Nauclea pobeguinii. J Nat Prod 1985; 48: 42-46
  CrossrefPubMedGoogle Scholar
• 8 Mesia K, Cimanga K, Tona L, Mampunza MM, Ntamabyaliro N, Muanda T, Muyembe T, Totté J, Pieters L, Vlietinck A. Assessment of the short-term safety and tolerability of a quantified 80 % ethanol extract from the stem bark of Nauclea pobeguinii (PR 259 CT1) in healthy volunteers: a clinical Phase I study. Planta Med 2011; 77: 111-116
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Mesia K, Lutete Tona L, Mampunza MM, Ntamabyaliro N, Tsobo M, Muyembe T, Cimanga K, Totté J, Mets T, Pieters L, Vlietinck AJ. Assessment of the antimalarial efficacy of PR 259 CT in human adult volunteers with diagnosed uncomplicated falciparum malaria. Part 1: a clinical Phase IIA trial. Planta Med 2012; 78: 211-218
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 PNLP. Echecs thérapeutiques à lʼartésunate-amodiaquine (ASAQ) et lʼartémether-luméfantrine (Coartem) chez les enfants de moins de 5 ans avec paludisme à P. falciparum en RD Congo, Février à Octobre 2005. Kinshasa: Ministère de la Santé, Programme National de Lutte Contre le Paludisme; 2005
  Google Scholar
• 11 Willcox ML, Graz B, Falquet J, Sidibé O, Forsterd M, Diallo D. Argemone mexicana decoction for the treatment of uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 2007; 101: 1190-1198
  CrossrefPubMedGoogle Scholar
• 12 WHO. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: WHO/HTM/RBM; 2003; 50 2003
  Google Scholar
• 13 WHO. Traditional practitioners as primary health care workers. Geneva: WHO/SHS/DHS/TRM; 95.6 1995
  Google Scholar
• 14 Benakis A, Paris M, Loutan L, Plessas CT, Plessas ST. Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers. Am Trop Med Hyg 1997; 56: 17-23
  PubMedGoogle Scholar
• 15 Newton P, Suputtamongkol Y, Teja-Isavadharm P, Pukrittayakamee S, Navaratnam V, Bates I, White N. Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44: 972-977
  CrossrefPubMedGoogle Scholar
• 16 Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet 1996; 30: 263-299
  CrossrefPubMedGoogle Scholar
• 17 Orrell C, Little F, Smith Folb P, Taylor W, Olliaro P, Barnes KI. Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur J Clin Pharmacol 2008; 64: 683-690
  CrossrefPubMedGoogle Scholar
• 18 Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M, Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna S, Lell B, Loolpapit M, Matsiegui PB, Missinou MA, Mwanza J, Ntoumi F, Olliaro P, Osimbo P, Rezbach P, Some E, Taylor WRJ. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 2002; 359: 1365-1372
  CrossrefPubMedGoogle Scholar
• 19 Adjuik M, Babiker A, Garner P, Olliaro P, Taylor WRJ, Whiteb NJ. Artesunate combination for treatment of malaria: meta-analysis. Lancet 2004; 363: 9-17
  CrossrefPubMedGoogle Scholar
• 20 Mokuolu OA, Okoro EO, Ayetoro SO, Adewara AA. Effect of artemisinin based treatment policy on consumption pattern of antimalarials. Am J Trop Med Hyg 2007; 76: 7-11
  PubMedGoogle Scholar
• 21 WHO. World malaria report 2008. Geneva: WHO/HTM/GMP; 2008.1 2008
  Google Scholar
• 22 Guthmann JP, Cohuet S, Rigutto C, Fortes F, Saraiva N, Kiguli J, Kyomuhendo J, Francis M, Noël F, Mulemba M, Balkan S. High efficacy of two artemisinin-based combinations (artesunate + amodiaquine and artemether + lumefantrine) in Caala, Central Angola. Am J Trop Med Hyg 2006; 75: 143-145
  PubMedGoogle Scholar
• 23 Meremikwu M, Alaribe A, Ejemot R, Oyo-Ita A, Ekenjoku J, Nwachukwu C, Ordu D, Ezedinachi E. Artemether-lumefantrine versus artesunate plus amodiaquine for treating uncomplicated childhood malaria in Nigeria: randomized controlled trial. Malaria J 2006; 5: 43
  CrossrefPubMedGoogle Scholar
• 24 Swarthout TD, Van De Boek IV, Kayembe G, Montgomery J, Pota H, Roper C. Artesunate + amodiaquine and Artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes. Trop Med Int Health 2006; 11: 1503-1511
  CrossrefPubMedGoogle Scholar
• 25 Brasseur P, Agnamey P, Gaye O, Vaillant M, Taylor WRJ, Olliaro PL. Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Sénégal. Malaria J 2007; 6: 150
  CrossrefPubMedGoogle Scholar
• 26 Faye B, Ndiaye JL, Ndiaye D, Dieng Y, Faye O, Gaye O. Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal. Malaria J 2007; 6: 80
  CrossrefPubMedGoogle Scholar
• 27 Sowunmi A, Balogun T, Gbotosho GO, Happi CT, Adedeji AA, Fehintola FA. Activities of amodiaquine, artesunate, and artesunate-amodiaquine against asexual- and sexual-stage parasites in falciparum malaria in children. Antimicrob Agents Chemother 2007; 51: 1694-1699
  CrossrefPubMedGoogle Scholar
• 28 Adjei GO, Kurtzhals JA, Rodrigues P, Alifrangis M, Hoegberg LC, Kitcher ED, Badoe EV, Lamptey R, Goka BQ. Amodiaquine-artesunate vs. artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malaria J 2008; 7: 127
  CrossrefPubMedGoogle Scholar
• 29 Falade CO, Ogundele AO, Yusuf BO, Ademowo OG, Ladipo SM. High efficacy of two artemisinin-based combinations (artemether-lumefantrine and artesunate plus amodiaquine) for acute uncomplicated malaria in Ibadan, Nigeria. Trop Med Int Health 2008; 13: 635-643
  CrossrefPubMedGoogle Scholar
• 30 Kobbe R, Klein P, Adjei S, Amemasor S, Thompson WN, Heidemann H, Nielsen MV, Vohwinkel J, Hogan B, Kreuels B, Bührlen M, Loag W, Ansong D, May J. A randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children. Malaria J 2008; 7: 261
  CrossrefPubMedGoogle Scholar
• 31 Owusu-Agyei S, Asante KP, Owusu R, Adjuik M, Amenga-Etego S, Dosoo DK, Gyapong J, Greenwood B, Chandramohan D. An open label, randomised trial of artesunate + amodiaquine, artesunate + chlorproguanil-dapsone and artemetherlumefantrine for the treatment of uncomplicated malaria. PLoS One 2008; 3: e2530
  CrossrefPubMedGoogle Scholar
• 32 Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJ. Amodiaquine alone, amodiaquine + sulfadoxine-pyrimethamine, amodiaquine + artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005; 365: 1474-1480
  CrossrefPubMedGoogle Scholar
• 33 Oyakhirome S, Pötschke M, Schwarz NG, Dörnemann J, Laengin M, Salazar CO, Lell B, Kun JF, Kremsner PG, Grobusch MP. Artesunate-amodiaquine combination therapy for falciparum malaria in young Gabonese children. Malaria J 2007; 6: 29
  CrossrefPubMedGoogle Scholar
• 34 Sowunmi A, Balogun ST, Gbotosho GO, Happi CT. Effects of amodiaquine, artesunate, and artesunate–amodiaquine on Plasmodium falciparum malaria-associated anaemia in children. Acta Trop 2009; 109: 55-60
  CrossrefPubMedGoogle Scholar
• 35 Olliaro P, Taylor WRJ. Phase scaling of artesunate-amodiaquine combination therapy for acute, uncomplicated falciparum malaria in the Oussouye District, Southern Sénégal. Geneva: WHO/CDS/TDR; unpublished data 2002
  Google Scholar
• 36 Maiteki-Sebuguzi C, Jagannathan P, Yau VM, Clark TD, Njama-Meya D, Nzarubara B, Talisuna AO, Kamya MR, Rosenthal PJ, Dorsey G, Staedke SG. Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Malaria J 2008; 7: 106
  CrossrefPubMedGoogle Scholar
• 37 Marsh K, Forster D, Waruiru C, Mwangi I, Winstanley M, Marsh V, Newton C, Winstaley P, Warn P, Peshu N, Pavol G, Snow R. Indicators of life threatening malaria in African children: clinical spectrum and simplified prognostic criteria. N Engl J Med 1995; 332: 1399-1404
  CrossrefPubMedGoogle Scholar
• 38 Van Hensbroek M, Onyiorah E, Jaffar S, Scheider G, Palmer A, Frenkel J, Ewere G, Forck S, Nusmeijes A, Benett S, Grenwod B. A trial of artemether or quinine in children with cerebral malaria. N Engl J Med 1996; 335: 69-75
  CrossrefPubMedGoogle Scholar
• 39 Orrell C, Taylor WR, Olliaro P. Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate. Trans R Soc Trop Med Hyg 2001; 95: 517-518
  CrossrefPubMedGoogle Scholar
• 40 Guévart E, Aguémon A. Deux hépatites fulminantes survenues au cours dʼun traitement curatif par lʼassociation artésunate-amodiaquine. Méd Mal Infect 2009; 39: 57-60
  PubMedGoogle Scholar
• 41 Willcox ML. A clinical trial of “AM”, a Ugandan herbal remedy for malaria. J Pub Health Med 1999; 21: 318-324
  CrossrefPubMedGoogle Scholar
• 42 Silverthorn DU. Human physiology: an integrated approach. New Jersey: Prentice Hall; 1998: 478
  Google Scholar
• 43 Taylor WRJ, White NJ. Antimalarial drug toxicity. A review. Drug Saf 2004; 27: 25-61
  Google Scholar
• 44 Maude RJ, Plewes C, Faiz MA, Hanson J, Charunwattana P, Lee SJ, Tärning J, Yunus EB, Hoque MG, Hasan MU, Hossain A, Lindegardh N, Day NPJ, White NJ, Dondorp AM. Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria?. Am J Trop Med Hyg 2009; 80: 126-132
  PubMedGoogle Scholar
• 45 White NJ. Cardiotoxicity of antimalarial drugs. Lancet 2007; 7: 549-558
  CrossrefPubMedGoogle Scholar
• 46 Ngouesse B, Basco LK, Ringwald P, Keundjian A, Blackett KN. Cardiac effects of amodiaquine and sulfadoxine-pyrimethamine in malaria-infected African patients. Am J Trop Med Hyg 2001; 65: 711-716
  PubMedGoogle Scholar
• 47 Hien TT, Day NPJ, Phu NH, Mai NTH, Chau TH, Loc PP, Singh DX, Chuong VL, Vinh H, Waller D, Chir B, Peto TEA, Phil D, Wite JN. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med 1996; 335: 76-83
  CrossrefPubMedGoogle Scholar
• 48 Karbwang J, Laothavorn P, Sukontason K, Thiha T, Rimchala W, Na-Bangchang K, Bunnag D. Effect of artemether on electrocardiogram in severe falciparum malaria. Southeast Asian J Trop Med Pub Health 1997; 28: 472-475
  PubMedGoogle Scholar
• 49 Benoit-Vical F, Valentin A, Dab B, Dakuyoc Z, Descamps L, Mallié M. NʼDribala (Cochlospermum planchonii) versus chloroquine for treatment of uncomplicated Plasmodium falciparum malaria. J Ethnopharmacol 2003; 89: 111-114
  CrossrefPubMedGoogle Scholar
• 50 Diallo D, Maïga B, Diakité C, Willcox M. Malarial-5: development of an antimalarial phytomedicine in Mali. In: Willcox M, Bodeker G, Rasoanaivo P, editors Traditional medicinal plants and malaria. Boca Raton: CRC Press; 2004: 117-130
  Google Scholar
• 51 Mueller MS, Runyambo N, Wagner I, Borrmann S, Dietz K, Heide L. Randomised controlled trial of a traditional preparation of Artemisia annua L. (annual wormwood) in the treatment of malaria. Trans R Soc Trop Med Hyg 2004; 98: 318-321
  Google Scholar
• 52 Winn D. Phyto-Laria: a promising herbal antimalarial from Ghana. The Africa Herbal Antimalaria Meeting, ICRAF House, Nairobi, Kenya, 20–22/3/2006. Available at http://www.worldagroforestry.org/treesandmarkets/antimalariameeting Accessed May 24, 2011
  PubMedGoogle Scholar
• 53 Willcox M, Benoit-Vical F, Fowler D, Bourdy G, Burford G, Giani S, Graziose R, Houghton P, Randrianarivelojosia M, Rasoanaivo P. Do ethnobotanical and laboratory data predict clinical safety and efficacy of anti-malarial plants?. Malaria J 2011; 10: S7
  CrossrefPubMedGoogle Scholar

• Supplementary Material